JDRF applauds Federal Government's budget commitments for research
OTTAWA (June 7, 2011) – Juvenile Diabetes Research Foundation (JDRF) applauds the Government of Canada for reaffirming its commitment to research and innovation.
As the leader in setting the agenda for type 1 diabetes research worldwide, and as the largest charitable funder and advocate of type 1 diabetes research, JDRF knows firsthand that partnership with government, academia and industry increases the value of research dollars exponentially.
In 2009, JDRF and the Government of Canada launched a $33.9 million partnership to establish a Canadian Clinical Trial Network (CCTN) to accelerate research advances for type 1 diabetes and its complications.
“The budget recognizes the critical role cutting-edge research and innovation plays in increasing both economic competitiveness and productivity” said Andrew McKee, President and CEO of JDRF Canada.
The budget includes a number of measures for Canada’s research community including:
- $65 million for Genome Canada to continue its revolutionary work in genomics and proteomics;
- $53.5 million over five years to support 10 new Canada Excellence Research Chairs;
- $100 million to help establish a Canada Brain Research Fund;
- $50 million over five years beginning in 2012-2013 to support the Perimeter Institute for Theoretical Physics; and
- Ongoing support for Canada’s three federal research granting councils.
“As a partner of the government’s first partnership to benefit the diabetes and diabetes research community, JDRF is pleased to see that the Government of Canada continues to support partnerships between private and public sectors which promote cutting-edge research, innovation and commercialization,” said McKee.
JDRF is the leading charitable funder and advocate of type 1 diabetes research worldwide. JDRF’s mission is to find a cure for diabetes and its complications through the support of research. JDRF funding and leadership is associated with most major scientific breakthroughs in type 1 diabetes research to date in Canada and around the world. It has raised more than $1.5 billion for diabetes research since its inception in 1970, including $107 million in 2010. JDRF raises funds in 7 countries, and is funding research in 19, including over 50 human clinical trials. For more information, please visit www.jdrf.ca.
The CCTN is a groundbreaking effort to accelerate made-in-Canada solutions for the management, care and cure of diabetes. The CCTN is currently developing several high-profile clinical trials, in association with leading diabetes researchers at partner universities and medical centers in Southern Ontario. The goal is to position Southern Ontario as an international hub for diabetes translational research, innovation, and commercialization of new therapeutics and enabling technologies and expand throughout Canada in the coming months. For more information, please visit jdrf.ca/cctn.
For more information please contact:
Jennifer Dent, JDRF